Matrix Metalloproteinase 3, Recombinant, Human (MMP-3, Stromelysin-1, SL-1, Transin)

Matrix metalloproteinases are important regulators of extracellular matrix molecules and cell-cell signaling and are involved in the regulation of the pericellular space, including the cleavage of matrix proteins. In particular, MMP3 has been shown to be effective in cleaving heparan sulfate proteoglycans. Purified recombinant MMP3 can directly cleave agrin, and it can also remove agrin from synaptic basal lamina. MMP3 activity is itself regulated as activation of MMP3 is lost in denervated muscles.\n\nRecombinant Human MMP-3 produced in HEK293 cells is a proform of the Human MMP3 [Tyr18-Cys477 (Lys45Glu)] and fused with a his-tag at the C-terminus. Matrix Metalloproteinase-3 is purified by proprietary chromatographic techniques.\n\nBiological Activity: \nThe activity was measured by its ability to cleave the fluorogenic peptide substrate, Mca-RPKPVE-Nval-WRK(Dnp)-NH2. The specific activity is > 150 pmoles/min/ug.\n\nStorage and Stability: \nLyophilized powder is stable for 12 months at -20 degrees C Reconstituted product must be stored in aliquots at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

M2421-12H

Size

2ug

Form

Supplied as a liquid in in Tris, CaCl2, NaCl and Brij35.

Purity

(same/more than) 98% as determined by RP-HPLC, anion-exchange FPLC and/or reducing and non-reducing SDS-PAGE Silver Stained gel.

References

1. Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarction. J Intern Med 2006 May;259(5):530-6\n2. Mu-calpain is involved in the regulation of TNF-alpha-induced matrix metalloproteinase-3 release in a rheumatoid synovial cell line. Biochem Biophys Res Commun 2006 May 12;343(3):937-42 3. IL-1 and TNF induction of matrix metalloproteinase-3 by c-Jun N-terminal kinase in trabecular meshwork. Invest Ophthalmol Vis Sci 2006 Apr;47(4):1469-76 4. The functional (-1171 5A-- > 6A) polymorphisms of matrix metalloproteinase 3 gene as a risk factor for oral submu cous fibrosis among male areca users. J Oral Pathol Med 2006 Feb;35(2):99-103 5. Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2006 Feb;77(2):185-8 6. Down-regulation of endometrial matrix metalloproteinase-3 and -7 expression in vitro and therapeutic regression of experimental endometriosis in vivo by a novel nonsteroidal progesterone receptor agonist, tanaproget. J Clin Endocrinol Metab 2006 Apr;91(4):1554-60